Affimed NV
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, … Read more
Affimed NV (AFMD) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: -0.648x
Based on the latest financial reports, Affimed NV (AFMD) has a cash flow conversion efficiency ratio of -0.648x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.13 Million) by net assets ($17.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Affimed NV - Cash Flow Conversion Efficiency Trend (2012–2023)
This chart illustrates how Affimed NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Affimed NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Affimed NV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Reliv International Inc
PINK:RELV
|
-0.027x |
|
Vivesto AB
ST:VIVE
|
-0.021x |
|
MOTHER
BK:MOTHER
|
N/A |
|
Export Inv
TA:EXPO
|
0.117x |
|
Asiaplast Industries Tbk
JK:APLI
|
-0.037x |
|
Brite Tech Bhd
KLSE:0011
|
0.060x |
|
Surefire Resources NL
AU:SRN
|
-0.100x |
|
Pipe Works L. Girakian Profil S.A.
AT:PROFK
|
-0.030x |
Annual Cash Flow Conversion Efficiency for Affimed NV (2012–2023)
The table below shows the annual cash flow conversion efficiency of Affimed NV from 2012 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $57.81 Million | $-110.27 Million | -1.908x | -178.09% |
| 2022-12-31 | $152.91 Million | $-104.89 Million | -0.686x | -7.70% |
| 2021-12-31 | $135.95 Million | $-86.59 Million | -0.637x | -136.36% |
| 2020-12-31 | $71.99 Million | $-19.40 Million | -0.269x | +64.14% |
| 2019-12-31 | $38.67 Million | $-29.06 Million | -0.751x | -160.99% |
| 2018-12-31 | $40.13 Million | $49.44 Million | 1.232x | +252.27% |
| 2017-12-31 | $31.58 Million | $-25.55 Million | -0.809x | +2.41% |
| 2016-12-31 | $38.75 Million | $-32.13 Million | -0.829x | -200.91% |
| 2015-12-31 | $67.27 Million | $-18.54 Million | -0.276x | +16.94% |
| 2014-12-31 | $31.80 Million | $-10.55 Million | -0.332x | -679.68% |
| 2013-12-31 | $-99.22 Million | $-5.68 Million | 0.057x | -51.60% |
| 2012-12-31 | $-73.12 Million | $-8.64 Million | 0.118x | -- |